Food Retention Risk Low for GLP-1 Users When Endoscopy Is Combined With Colonoscopy
(MedPage Today) — Patients on GLP-1 receptor agonists had a low risk of food retention when an esophagogastroduodenoscopy (EGD) was combined with a colonoscopy, a small retrospective study found.
Among more than 200 adults in the analysis, there…
Report: Breast cancer mortality continues three decade decline, but steeper increases in incidence for some women
The American Cancer Society (ACS) has released Breast Cancer Statistics, 2024, the organization’s biennial update on breast cancer occurrence and trends in the United States.
Jill Martin on unexpected friendship during breast cancer treatment
TODAY’s Jill Martin and her friend, Soul Cycle founding instructor Stacey Griffith, share their story of forming a bond and sisterhood of support while undergoing chemo together to treat breast cancer. They reflect on their diagnoses and life after being cancer-free.
Basketball stars open up about impact of breast cancer in their lives
WNBA’s Kahleah Cooper and NBA’s Donovan Clingan open up about how they have been personally impacted by breast cancer. Dr. Susan Domchek speaks on the importance of genetic testing for prevention and early detection and TODAY’s Jill Martin shares her own journey and how it inspired her to team up her clothing brand with the NBA and WNBA to raise awareness.
Precision breast cancer trial shows improved treatment by tumor subtype
Despite recent advances in the treatment of breast cancer, it remains the second leading cause of cancer death in the U.S. and worldwide. There is a continued need to improve treatment strategies and therapies that not only improve patient survival, and also reduce long-term treatment-related toxicities.
New ACS Report: Breast Cancer Mortality Continues Three Decade Decline Overall, but Steeper Increases in Incidence for Women <50 & Asian American, Pacific Islanders of all Ages
American Cancer Society researchers also report alarming disparities remain for underserved populations, including Native American women
Breast Cancer Continues to Rise Among Younger Women, Study Finds
Death rates are declining among U.S. women with breast cancer. But the disease is turning up more often in women under age 50.
Breast cancer rising among younger women and Asian Americans, report finds
Americans have benefited from huge leaps in breast cancer treatment over the last two decades, but diagnoses are becoming more common, especially among younger women.
Aspirin vs Placebo as Adjuvant Therapy for Breast Cancer—Reply
In Reply Alliance A011502, a randomized trial of aspirin 300 mg daily compared with placebo among 3020 survivors of high-risk nonmetastatic breast cancer, was terminated early due to lack of benefit from aspirin. Dr Thorat and colleagues note that for some cancers (eg, colorectal cancer) and different settings (eg, primary prevention), the time course of benefit can differ. However, in the adjuvant setting, it would still be most appropriate to use the standard stopping rules applied to adjuvant treatments such as hormonal therapy for hormone receptor–positive cancers, which, as Thorat and colleagues point out, can have a more indolent course with late recurrences. In our trial, the futility bound was crossed with a numerically worse hazard ratio for invasive disease–free survival (hazard ratio, 1.27; 95% CI, 0.99-1.63; P = .06), making it unlikely that a benefit would have been observed with further follow-up.
Aspirin vs Placebo as Adjuvant Therapy for Breast Cancer
To the Editor The Alliance A011502 trial was stopped early for futility at a median duration of just over 1.5 years and a follow-up of less than 3 years. The mechanisms of action and optimal dose associated with aspirin’s cancer-preventive effect remain an area of active research. Trials such as Add-Aspirin and CaPP3 (ISRCTN16261285) are comparing different doses of aspirin in both the adjuvant setting and among individuals with Lynch syndrome. However, prior data make clear that aspirin’s beneficial effect on cancer incidence and mortality does not emerge until at least 5 to 10 years of follow-up and likely persists for at least 10 years after cessation of use. These unique features of aspirin’s preventive effects are particularly relevant for malignancies with a low risk of early events and deaths, such as hormone receptor–positive breast cancer, in which the annual hazards of recurrence are low but remain stable during a prolonged period, up to 20 years. The eligibility criteria of this trial were revised according to this rationale. Almost 90% of the participants in the Alliance A011502 trial were women with hormone receptor–positive breast cancer. Therefore, the number of events accrued at the early-stoppage decision likely represented only a fraction of events that would be expected in the long term. In this context, we suggest that the futility therefore should not have been based on typical statistical criteria but rather should have also considered the unique pharmacology of aspirin and the natural history of breast cancer, for which longer follow-up, as originally planned, would have been more informative.